Bartholomeus C. M. Haarman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bartholomeus C. M. Haarman has a total of 667 co-authors. Here are the top co-authors by number of shared publications:
- Eduard Vieta
Hospital Clínic de Barcelona
9 shared publications - Joaquim Radua
IDIBAPS, CIBERSAM, Institute of Neuroscience University of Barcelona Barcelona Spain
9 shared publications - Tomas Hajek
Dalhousie University
8 shared publications Raymond Salvador
7 shared publications- Erick Jorge Canales-Rodríguez
University of Granada
6 shared publications - Francesco Benedetti
Vita‐Salute San Raffaele University Milan Italy
6 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Research Square
Individualized Structural Brain Deviations in Bipolar I Disorder: a Normative Modeling Study of 4 660 ENIGMA Participants
Bipolar disorder (BD) is a prevalent psychiatric condition characterized by marked clinical and neuroanatomical heterogeneity. Prior neuroimaging studies have used case-control comparisons yielding small to moderate effect sizes for group differences. Large and diverse samples are needed to map heterogeneity within BD. Here, we used individualized brain morphometry deviations derived from normative modeling for three MRI-based measures (regional cortical thickness, regional surface area, and subcortical volumes). We applied this approach to a large international sample of 4 660 individuals (1 145 with bipolar I disorder and 3 515 healthy controls) from the ENIGMA Bipolar Disorder Working Group consortium (age range = 8–80, female = 53.15%) and examined the distribution of deviations within the bipolar disorder group, differences between healthy controls and individuals with bipolar disorder, and associations between neuroanatomical deviations and clinical variables. We found that individuals with bipolar disorder showed a higher proportion of localized extreme deviations, notably negative cortical thickness deviations in regions consistently reported as thinner in prior studies (the left superior frontal gyrus, bilateral inferior frontal gyrus (pars opercularis), left precuneus) and subcortical volume negative deviations in the left hippocampus. In addition, ROI-level deviations in the left middle temporal gyrus and the left inferior temporal gyrus were associated with longer illness duration. This is the largest study to date exploring individualized deviations as neuroanatomical features associated with bipolar disorder. Our findings suggest that neuroanatomical heterogeneity is a core feature of bipolar disorder, with preferential left-lateralized cortical-hippocampal involvement pointing to spatially structured heterogeneity.
- 4 November 2026
- Published by Springer Nature in Research Square
Open AccessIndividualized Structural Brain Deviations in Bipolar I Disorder: a Normative Modeling Study of 4 660 ENIGMA Participants
Bipolar disorder (BD) is a prevalent psychiatric condition characterized by marked clinical and neuroanatomical heterogeneity. Prior neuroimaging studies have used case-control comparisons yielding small to moderate effect sizes for group differences. Large and diverse samples are needed to map heterogeneity within BD. Here, we used individualized brain morphometry deviations derived from normative modeling for three MRI-based measures (regional cortical thickness, regional surface area, and subcortical volumes). We applied this approach to a large international sample of 4 660 individuals (1 145 with bipolar I disorder and 3 515 healthy controls) from the ENIGMA Bipolar Disorder Working Group consortium (age range = 8–80, female = 53.15%) and examined the distribution of deviations within the bipolar disorder group, differences between healthy controls and individuals with bipolar disorder, and associations between neuroanatomical deviations and clinical variables. We found that individuals with bipolar disorder showed a higher proportion of localized extreme deviations, notably negative cortical thickness deviations in regions consistently reported as thinner in prior studies (the left superior frontal gyrus, bilateral inferior frontal gyrus (pars opercularis), left precuneus) and subcortical volume negative deviations in the left hippocampus. In addition, ROI-level deviations in the left middle temporal gyrus and the left inferior temporal gyrus were associated with longer illness duration. This is the largest study to date exploring individualized deviations as neuroanatomical features associated with bipolar disorder. Our findings suggest that neuroanatomical heterogeneity is a core feature of bipolar disorder, with preferential left-lateralized cortical-hippocampal involvement pointing to spatially structured heterogeneity.
- Open Access
- 11 September 2026
- Published by Center for Open Science in PsyArXiv
Combined sleep deprivation and light therapy for depression in major depressive disorder and bipolar disorder
Background. Combined chronotherapy, a combination of sleep deprivation and light therapy, offers a promising approach to accelerating improvement in depression. Therapeutic sleep deprivation can have a rapid antidepressant effect, while light therapy and regulation of sleep timing are intended to maintain the initial benefit. This review examines the evidence supporting further clinical evaluation of combined chronotherapy in major depressive disorder (MDD) and bipolar disorder (BD).Methods. We examined literature identified through PubMed/MEDLINE, Embase, Europe PMC and citation searching, with the latest search conducted on 9 September 2026. Narrative synthesis was used to examine speed and persistence of response, clinical applicability and tolerability. Controlled studies of combined chronotherapy, studies of individual treatment components and observational studies were considered separately, with repeated reports linked where identifiable. We interpreted outcomes in relation to treatment schedules, comparators and study limitations.Results. Seven randomised trials in adult patients with a depressive episode evaluated early antidepressant effects of combined chronotherapy. Several trials found rapid improvement, with benefits extending into follow-up, and outpatient studies support feasibility beyond inpatient settings. The most recent trial, including 44 randomised adults with masked outcome assessment, found greater improvement from day 5 through day 12 and discharge. Findings were not consistent across studies: one trial found an advantage confined to the first week, while two found no significant benefit on their primary comparisons. Studies of individual treatment components and clinical cohorts provide additional evidence on maintenance, patient selection and delivery.Conclusions. Combined chronotherapy is a promising adjunctive treatment for depression in MDD and BD, with evidence of rapid improvement and persistence of benefit in some trials. Findings vary across treatment protocols and settings, and the magnitude and durability of benefit remain uncertain. Further adequately powered randomised trials are needed to establish its clinical role.
- 11 September 2026
- Published by Center for Open Science in PsyArXiv
Open AccessCombined sleep deprivation and light therapy for depression in major depressive disorder and bipolar disorder
Background. Combined chronotherapy, a combination of sleep deprivation and light therapy, offers a promising approach to accelerating improvement in depression. Therapeutic sleep deprivation can have a rapid antidepressant effect, while light therapy and regulation of sleep timing are intended to maintain the initial benefit. This review examines the evidence supporting further clinical evaluation of combined chronotherapy in major depressive disorder (MDD) and bipolar disorder (BD).Methods. We examined literature identified through PubMed/MEDLINE, Embase, Europe PMC and citation searching, with the latest search conducted on 9 September 2026. Narrative synthesis was used to examine speed and persistence of response, clinical applicability and tolerability. Controlled studies of combined chronotherapy, studies of individual treatment components and observational studies were considered separately, with repeated reports linked where identifiable. We interpreted outcomes in relation to treatment schedules, comparators and study limitations.Results. Seven randomised trials in adult patients with a depressive episode evaluated early antidepressant effects of combined chronotherapy. Several trials found rapid improvement, with benefits extending into follow-up, and outpatient studies support feasibility beyond inpatient settings. The most recent trial, including 44 randomised adults with masked outcome assessment, found greater improvement from day 5 through day 12 and discharge. Findings were not consistent across studies: one trial found an advantage confined to the first week, while two found no significant benefit on their primary comparisons. Studies of individual treatment components and clinical cohorts provide additional evidence on maintenance, patient selection and delivery.Conclusions. Combined chronotherapy is a promising adjunctive treatment for depression in MDD and BD, with evidence of rapid improvement and persistence of benefit in some trials. Findings vary across treatment protocols and settings, and the magnitude and durability of benefit remain uncertain. Further adequately powered randomised trials are needed to establish its clinical role.
- 19 August 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
The Association Between Lithium Use and Physical Comorbidities Across Age Groups: A Cross‐Sectional Study From the Global Aging and Geriatric Experiments in Bipolar Disorder ( GAGE ‐ BD ) Project
Introductions: Lithium remains the first‐line maintenance treatment for bipolar disorder (BD), yet its safety in older‐age BD (OABD) is uncertain due to limited large‐scale data. OABD patients often experience more severe physical comorbidities compared to younger BD patients, but systematic evidence regarding lithium's association with these conditions is lacking. This study examined the association between lithium use and physical comorbidities across age groups using the international Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE‐BD) dataset. Methods: A cross‐sectional analysis was conducted using combined Wave 1 and 2 data from GAGE‐BD project, encompassing 37 studies from 20 sites worldwide. Participants aged ≥ 18 years with BD were classified according to current lithium use. Physical comorbidities were harmonised into eight organ‐system domains. Sociodemographic and clinical variables were compared between individuals receiving lithium treatment and those not prescribed lithium. Generalised linear mixed models adjusted for age, site and lithium × age interaction were applied to evaluate associations with physical comorbidities. Results: Of the 2873 total participants included in the study, 1069 were currently receiving lithium treatment and 1804 were not prescribed lithium. Participants treated with lithium showed a lower overall prevalence of physical comorbidities compared with those not receiving lithium. Regression analyses revealed significant age‐by‐lithium interactions for cardiovascular (χ 2 = 9.27, p = 0.002), respiratory (χ 2 = 7.56, p = 0.006), genitourinary (χ 2 = 8.66, p = 0.003) and endocrine (χ 2 = 16.96, p < 0.001) comorbidities. Model‐estimated curve crossings occurred at approximately 43 years (cardiovascular), 32 years (respiratory), 51 years (genitourinary) and 59 years (endocrine), above which predicted prevalence was lower among participants treated with lithium, whereas no differences were observed for gastrointestinal, hepatic, renal or musculoskeletal systems. Conclusions: Lithium use in OABD was associated with a lower burden of specific physical comorbidities, particularly cardiovascular, respiratory and endocrine conditions. Although prescription bias cannot be excluded, the findings challenge the perception that lithium exacerbates physical health risks in older adults. Instead, they support lithium's continued use—with appropriate monitoring—as a safe and effective treatment option for OABD, and highlight the need for prospective studies to further clarify the relationship between lithium exposure and physical health outcomes.
- 19 August 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
The Association Between Lithium Use and Physical Comorbidities Across Age Groups: A Cross‐Sectional Study From the Global Aging and Geriatric Experiments in Bipolar Disorder ( GAGE ‐ BD ) Project
Introductions: Lithium remains the first‐line maintenance treatment for bipolar disorder (BD), yet its safety in older‐age BD (OABD) is uncertain due to limited large‐scale data. OABD patients often experience more severe physical comorbidities compared to younger BD patients, but systematic evidence regarding lithium's association with these conditions is lacking. This study examined the association between lithium use and physical comorbidities across age groups using the international Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE‐BD) dataset. Methods: A cross‐sectional analysis was conducted using combined Wave 1 and 2 data from GAGE‐BD project, encompassing 37 studies from 20 sites worldwide. Participants aged ≥ 18 years with BD were classified according to current lithium use. Physical comorbidities were harmonised into eight organ‐system domains. Sociodemographic and clinical variables were compared between individuals receiving lithium treatment and those not prescribed lithium. Generalised linear mixed models adjusted for age, site and lithium × age interaction were applied to evaluate associations with physical comorbidities. Results: Of the 2873 total participants included in the study, 1069 were currently receiving lithium treatment and 1804 were not prescribed lithium. Participants treated with lithium showed a lower overall prevalence of physical comorbidities compared with those not receiving lithium. Regression analyses revealed significant age‐by‐lithium interactions for cardiovascular (χ 2 = 9.27, p = 0.002), respiratory (χ 2 = 7.56, p = 0.006), genitourinary (χ 2 = 8.66, p = 0.003) and endocrine (χ 2 = 16.96, p < 0.001) comorbidities. Model‐estimated curve crossings occurred at approximately 43 years (cardiovascular), 32 years (respiratory), 51 years (genitourinary) and 59 years (endocrine), above which predicted prevalence was lower among participants treated with lithium, whereas no differences were observed for gastrointestinal, hepatic, renal or musculoskeletal systems. Conclusions: Lithium use in OABD was associated with a lower burden of specific physical comorbidities, particularly cardiovascular, respiratory and endocrine conditions. Although prescription bias cannot be excluded, the findings challenge the perception that lithium exacerbates physical health risks in older adults. Instead, they support lithium's continued use—with appropriate monitoring—as a safe and effective treatment option for OABD, and highlight the need for prospective studies to further clarify the relationship between lithium exposure and physical health outcomes.
- Open Access
- 10 July 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (5) , e70141
Essential Information About Chronobiology and Chronotherapy for the Optimal Care of People With Bipolar Disorders: An Expert Consensus
Introduction: Circadian dysfunction is involved in the pathophysiology of bipolar disorders (BD), and circadian‐based interventions are gaining recognition in their management. Moreover, basic and epidemiologic research has generated findings inspiring circadian‐informed self‐ and clinician‐management strategies. Despite these gains, many Clinical Practice Guidelines and clinical training programs have not incorporated this evidence in their recommendations and curricula. This International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force position paper reports a Delphi‐based expert consensus on what is essential for mental health clinicians to know about the chronobiology and chronotherapy of BD. Methods: An initial pool of statements was extracted from academic and grey literature, and experts could suggest additional statements. Statements were rated on a 5‐point scale (‘essential’; ‘important’; ‘don't know/depends’; ‘unimportant’; ‘should not be included’). Consensus was reached when statements were rated as essential or important by ≥ 80% of experts. Results: Thirty experts from 15 countries in Europe, North and South America, and the Asia Pacific participated (mean age of 55.3 years [SD = 11.8]; 40% female; 83% psychiatrists; mean clinical experience of 26 years [SD = 10.8]). Eight‐hundred‐and‐thirty‐seven statements were rated across three rounds. Consensus was reached on 342 statements spanning four major themes: basic circadian science; circadian health and disruption; chronobiology of BD; and six chronotherapies (e.g., protocols, outcomes, risks/contraindications). Conclusions: An expert consensus was obtained on the essential information about the chronobiology and chronotherapy of BD, intended to help clinicians optimise their management of BD. Dissemination of this knowledge is expected to enhance the training and efficacy of clinicians.
- 10 July 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (5) , e70141
Open AccessEssential Information About Chronobiology and Chronotherapy for the Optimal Care of People With Bipolar Disorders: An Expert Consensus
Introduction: Circadian dysfunction is involved in the pathophysiology of bipolar disorders (BD), and circadian‐based interventions are gaining recognition in their management. Moreover, basic and epidemiologic research has generated findings inspiring circadian‐informed self‐ and clinician‐management strategies. Despite these gains, many Clinical Practice Guidelines and clinical training programs have not incorporated this evidence in their recommendations and curricula. This International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force position paper reports a Delphi‐based expert consensus on what is essential for mental health clinicians to know about the chronobiology and chronotherapy of BD. Methods: An initial pool of statements was extracted from academic and grey literature, and experts could suggest additional statements. Statements were rated on a 5‐point scale (‘essential’; ‘important’; ‘don't know/depends’; ‘unimportant’; ‘should not be included’). Consensus was reached when statements were rated as essential or important by ≥ 80% of experts. Results: Thirty experts from 15 countries in Europe, North and South America, and the Asia Pacific participated (mean age of 55.3 years [SD = 11.8]; 40% female; 83% psychiatrists; mean clinical experience of 26 years [SD = 10.8]). Eight‐hundred‐and‐thirty‐seven statements were rated across three rounds. Consensus was reached on 342 statements spanning four major themes: basic circadian science; circadian health and disruption; chronobiology of BD; and six chronotherapies (e.g., protocols, outcomes, risks/contraindications). Conclusions: An expert consensus was obtained on the essential information about the chronobiology and chronotherapy of BD, intended to help clinicians optimise their management of BD. Dissemination of this knowledge is expected to enhance the training and efficacy of clinicians.
- Open Access
Efficacy of an Anti-Inflammatory Dietary Pattern on Global Functioning, Gut Microbiome, and Health in Patients with Psychiatric Disorders and Neurodegenerative Diseases: Protocol for a Randomized Controlled Crossover Trial
Background: Psychiatric disorders and neurodegenerative diseases, including bipolar disorder (BD), schizophrenia spectrum disorders (SSD), Parkinson’s disease (PD), and Alzheimer’s disease (AD), are associated with substantial impairments in functioning and quality of life. Increasing evidence suggests that low-grade systemic inflammation and gut microbiome dysregulation are shared mechanisms across these brain disorders, providing a rationale for transdiagnostic interventions targeting the gut–brain axis. Objective: This study was designed to evaluate the efficacy of an anti-inflammatory dietary pattern (AIDP), termed the BrAIN diet, on global functioning and a comprehensive set of secondary clinical, cognitive, inflammatory, and gut-health outcomes across relevant patient populations. Methods: We designed an open-label, randomized controlled, two-period crossover trial with 12-week intervention periods, a 24-week washout period and 12-week follow-up. We aimed to enrol 100 adult outpatients (25 per diagnosis: BD, SSD, PD, and AD) aged 18–80 years, recruited through outpatient clinics and patient organisations in the northern Netherlands. Participants were randomized 1:3 to either start the BrAIN diet immediately (Group 1, BrAIN/diet-as-usual [DaU] sequence) or after 36-weeks (Group 2, DaU/BrAIN sequence). The BrAIN diet is based on Shivappa’s Dietary Inflammatory Index, components of the MIND diet, and Dutch dietary guidelines, and is delivered through weekly home-delivered food boxes, recipes, and weekly dietitian counselling. The primary outcome is global functioning measured with the Outcome Questionnaire-45 (OQ-45). The treatment effect is estimated from the timepoint × treatment interaction in a linear mixed-effects model that uses all observed timepoints, with participant as a random intercept and period and sequence as fixed effects. Secondary outcomes include Global Assessment of Functioning (GAF), cognition (Brief Assessment of Cognition, Stroop, Trail Making), quality of life (EQ-5D), fatigue (FSS), gastrointestinal symptoms (GSRS), gut-permeability biomarkers, faecal microbiome composition, inflammatory and metabolic markers, and disease-specific symptom scales. Assessments occur at weeks 0 (V1, baseline period 1), 12 (V2, end of period 1), 24 (V3, mid-washout), 36 (V4, baseline period 2), 48 (V5, end of period 2), and 60 (V6, follow-up). The trial protocol was developed in 2021 and approved by the accredited Medical Research Ethics Committee on 11 January 2022. The trial is reported in accordance with the SPIRIT 2013 guideline in effect at the time of protocol development. Results: The trial received favourable ethical opinion from Medical Research Ethics Committee BeBo Assen (NL78755.056.21) on 11 January 2022 and was registered prospectively at OMON (NL-OMON52339). Recruitment commenced in February 2022; the first participant was enrolled on 7 March 2022 and the last on 6 May 2024. Follow-up was completed on 5 September 2025. A total of 107 participants were enrolled. Data analysis is ongoing; primary results are expected to be submitted for publication in summer 2026. Conclusions: This study provides evidence on whether an anti-inflammatory dietary intervention targeting shared inflammatory and gut–microbiome pathways can improve global functioning and a broad set of clinical and mechanistic outcomes in psychiatric and neurodegenerative populations. The crossover design ensures all participants ultimately receive the intervention while serving as their own controls, maximising statistical power within a heterogeneous patient population. If effective, the BrAIN diet could provide a safe, accessible adjunct to standard care in neuropsychiatric and neurodegenerative populations. Trial Registration: OMON NL-OMON52339; https://onderzoekmetmensen.nl/en/trial/52339
Open AccessEfficacy of an Anti-Inflammatory Dietary Pattern on Global Functioning, Gut Microbiome, and Health in Patients with Psychiatric Disorders and Neurodegenerative Diseases: Protocol for a Randomized Controlled Crossover Trial
Background: Psychiatric disorders and neurodegenerative diseases, including bipolar disorder (BD), schizophrenia spectrum disorders (SSD), Parkinson’s disease (PD), and Alzheimer’s disease (AD), are associated with substantial impairments in functioning and quality of life. Increasing evidence suggests that low-grade systemic inflammation and gut microbiome dysregulation are shared mechanisms across these brain disorders, providing a rationale for transdiagnostic interventions targeting the gut–brain axis. Objective: This study was designed to evaluate the efficacy of an anti-inflammatory dietary pattern (AIDP), termed the BrAIN diet, on global functioning and a comprehensive set of secondary clinical, cognitive, inflammatory, and gut-health outcomes across relevant patient populations. Methods: We designed an open-label, randomized controlled, two-period crossover trial with 12-week intervention periods, a 24-week washout period and 12-week follow-up. We aimed to enrol 100 adult outpatients (25 per diagnosis: BD, SSD, PD, and AD) aged 18–80 years, recruited through outpatient clinics and patient organisations in the northern Netherlands. Participants were randomized 1:3 to either start the BrAIN diet immediately (Group 1, BrAIN/diet-as-usual [DaU] sequence) or after 36-weeks (Group 2, DaU/BrAIN sequence). The BrAIN diet is based on Shivappa’s Dietary Inflammatory Index, components of the MIND diet, and Dutch dietary guidelines, and is delivered through weekly home-delivered food boxes, recipes, and weekly dietitian counselling. The primary outcome is global functioning measured with the Outcome Questionnaire-45 (OQ-45). The treatment effect is estimated from the timepoint × treatment interaction in a linear mixed-effects model that uses all observed timepoints, with participant as a random intercept and period and sequence as fixed effects. Secondary outcomes include Global Assessment of Functioning (GAF), cognition (Brief Assessment of Cognition, Stroop, Trail Making), quality of life (EQ-5D), fatigue (FSS), gastrointestinal symptoms (GSRS), gut-permeability biomarkers, faecal microbiome composition, inflammatory and metabolic markers, and disease-specific symptom scales. Assessments occur at weeks 0 (V1, baseline period 1), 12 (V2, end of period 1), 24 (V3, mid-washout), 36 (V4, baseline period 2), 48 (V5, end of period 2), and 60 (V6, follow-up). The trial protocol was developed in 2021 and approved by the accredited Medical Research Ethics Committee on 11 January 2022. The trial is reported in accordance with the SPIRIT 2013 guideline in effect at the time of protocol development. Results: The trial received favourable ethical opinion from Medical Research Ethics Committee BeBo Assen (NL78755.056.21) on 11 January 2022 and was registered prospectively at OMON (NL-OMON52339). Recruitment commenced in February 2022; the first participant was enrolled on 7 March 2022 and the last on 6 May 2024. Follow-up was completed on 5 September 2025. A total of 107 participants were enrolled. Data analysis is ongoing; primary results are expected to be submitted for publication in summer 2026. Conclusions: This study provides evidence on whether an anti-inflammatory dietary intervention targeting shared inflammatory and gut–microbiome pathways can improve global functioning and a broad set of clinical and mechanistic outcomes in psychiatric and neurodegenerative populations. The crossover design ensures all participants ultimately receive the intervention while serving as their own controls, maximising statistical power within a heterogeneous patient population. If effective, the BrAIN diet could provide a safe, accessible adjunct to standard care in neuropsychiatric and neurodegenerative populations. Trial Registration: OMON NL-OMON52339; https://onderzoekmetmensen.nl/en/trial/52339
- Open Access
Demographic and Clinical Correlates of Body Mass Index in Older Age Bipolar Disorder: Results from the GAGE-BD Project
Background and Objectives: There are known associations between bipolar disorder and obesity, but it has not been well characterized in older adults with bipolar disorder (OABD). This study aims to examine body mass index (BMI) and its clinical correlations in OABD. Materials and Methods: A secondary analysis was conducted using data from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) project, an international harmonized dataset of OABD cohorts. To examine the relationship between BMI and clinical characteristics (e.g., sex, psychiatric history, symptom severity, medication use, comorbidities), multivariable linear regression and multinomial logistic regression models with random effect for study cohort were used, with BMI as a continuous and as an ordinal (underweight vs. healthy weight vs. overweight vs. obese) dependent variable, respectively. Results: Of 1,226 OABD participants with BMI data, 405 (33.0%) were classified as overweight (BMI 25–29.99) and 462 (37.7%) as obese (BMI > 30). In linear regression models, higher BMI was associated with younger age, higher number of somatic comorbidities, and anticonvulsant use, while lower BMI was associated with lithium use. In logistic regression models, obesity was associated with cardiovascular comorbidity, musculoskeletal comorbidity and endocrine comorbidity. Conclusions: A high proportion of individuals with OABD are overweight or obese. Several demographic and clinical correlations of higher BMI were found, including younger age, higher number of medical comorbidities and anticonvulsant use. Clinicians should monitor and manage weight changes and associated comorbidities, and promote lifestyle and health interventions to minimize the risk of negative health outcomes associated with high BMI.
Open AccessDemographic and Clinical Correlates of Body Mass Index in Older Age Bipolar Disorder: Results from the GAGE-BD Project
Background and Objectives: There are known associations between bipolar disorder and obesity, but it has not been well characterized in older adults with bipolar disorder (OABD). This study aims to examine body mass index (BMI) and its clinical correlations in OABD. Materials and Methods: A secondary analysis was conducted using data from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) project, an international harmonized dataset of OABD cohorts. To examine the relationship between BMI and clinical characteristics (e.g., sex, psychiatric history, symptom severity, medication use, comorbidities), multivariable linear regression and multinomial logistic regression models with random effect for study cohort were used, with BMI as a continuous and as an ordinal (underweight vs. healthy weight vs. overweight vs. obese) dependent variable, respectively. Results: Of 1,226 OABD participants with BMI data, 405 (33.0%) were classified as overweight (BMI 25–29.99) and 462 (37.7%) as obese (BMI > 30). In linear regression models, higher BMI was associated with younger age, higher number of somatic comorbidities, and anticonvulsant use, while lower BMI was associated with lithium use. In logistic regression models, obesity was associated with cardiovascular comorbidity, musculoskeletal comorbidity and endocrine comorbidity. Conclusions: A high proportion of individuals with OABD are overweight or obese. Several demographic and clinical correlations of higher BMI were found, including younger age, higher number of medical comorbidities and anticonvulsant use. Clinicians should monitor and manage weight changes and associated comorbidities, and promote lifestyle and health interventions to minimize the risk of negative health outcomes associated with high BMI.
- 27 March 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (8) , 4418-4432
Cortical morphometry might predict currently prescribed vs. discontinued medications in bipolar disorder, even after controlling for the cumulative dose effects: An ENIGMA mega-analysis
Recent research suggests that brain anatomy may help identify the most effective pharmacological treatment for each individual with bipolar disorder and reduce trial-and-error prescribing. We aimed to investigate whether brain anatomy predicts whether a medication is currently prescribed or has been discontinued, as a proxy for treatment effectiveness. The rationale is that medications that provide clinical benefit without unacceptable side effects are likely to be continued, whereas those with limited benefit or poor tolerability are typically discontinued. We used T1-weighted MRI from twelve ENIGMA-BD cohorts (n = 2462; 473 individuals with BD [61% female, age 18-73] and 1989 controls) to derive regional cortical thickness and surface area and subcortical volumes. Site differences were harmonized using ComBat models fitted on controls' data. Within cross-validation, models were trained to first adjust for cumulative dose and other covariates and then predict medication status. On test sets, current prescription (vs. discontinuation) of lithium was predicted by greater cortical thickness and reduced surface area, whereas current prescription (vs. discontinuation) of antidepressants and atypical antipsychotics was predicted by greater cortical thickness. Predictive regions for atypical antipsychotics were generally consistent across subgroups of age, gender, illness duration, and history of psychosis, and in the largest site, and differed from those associated with cumulative effects of medication on the cortex. Predictions were poor for subcortical volumes and for antiepileptic mood stabilizers and typical antipsychotics. These findings provide preliminary support that cortical anatomy may help inform future development of biomarkers for treatment selection, pending validation in longitudinal studies.
- 27 March 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (8) , 4418-4432
Cortical morphometry might predict currently prescribed vs. discontinued medications in bipolar disorder, even after controlling for the cumulative dose effects: An ENIGMA mega-analysis
Recent research suggests that brain anatomy may help identify the most effective pharmacological treatment for each individual with bipolar disorder and reduce trial-and-error prescribing. We aimed to investigate whether brain anatomy predicts whether a medication is currently prescribed or has been discontinued, as a proxy for treatment effectiveness. The rationale is that medications that provide clinical benefit without unacceptable side effects are likely to be continued, whereas those with limited benefit or poor tolerability are typically discontinued. We used T1-weighted MRI from twelve ENIGMA-BD cohorts (n = 2462; 473 individuals with BD [61% female, age 18-73] and 1989 controls) to derive regional cortical thickness and surface area and subcortical volumes. Site differences were harmonized using ComBat models fitted on controls' data. Within cross-validation, models were trained to first adjust for cumulative dose and other covariates and then predict medication status. On test sets, current prescription (vs. discontinuation) of lithium was predicted by greater cortical thickness and reduced surface area, whereas current prescription (vs. discontinuation) of antidepressants and atypical antipsychotics was predicted by greater cortical thickness. Predictive regions for atypical antipsychotics were generally consistent across subgroups of age, gender, illness duration, and history of psychosis, and in the largest site, and differed from those associated with cumulative effects of medication on the cortex. Predictions were poor for subcortical volumes and for antiepileptic mood stabilizers and typical antipsychotics. These findings provide preliminary support that cortical anatomy may help inform future development of biomarkers for treatment selection, pending validation in longitudinal studies.
- Open Access
- 7 February 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (2) , 100
Can Physical Activity, Sleep Parameters, and Sleep–Wake Patterns Predict Outcome of Combined Chronotherapy in Mood Disorder During Routine Clinical Practice? An Exploratory Study
Background/Objectives: Combined chronotherapy (CCT), which combines repeated sleep deprivation and light therapy, is used in the clinical treatment of severe depression. Despite its potential to rapidly reduce depressive symptoms, CCT is infrequently used in clinical practice. We explored whether actigraphy-derived within-patient changes in physical activity, sleep parameters, and sleep–wake patterns prior to CCT can help identify those most likely to benefit from this treatment, supporting personalized mental health care. Methods: Actigraphy data from nine severely depressed patients were collected before, during, and after CCT. Data were assessed with a questionnaire on depressive symptoms (Inventory of Depressive Symptomatology—Self Report, IDS-SR) and actigraphy measures for sleep–wake patterns and physical activity: daily mean activity level, rhythm (intradaily variability (IV), interdaily stability (IS)), Midpoint of Sleep (MSF), time in bed, sleep efficiency (SE), and the fragmentation index (FI). Variables were compared before and after CCT by systematic visual inspection due to the small sample size. A prior set Minimal Clinically Important Difference (MCID) of a 30% change in IDS scores from before and the week after CCT was used to categorize patients as responders (n = 3) or nonresponders (n = 6) to CCT. Results: After CCT, for both responders and nonresponders, there was a notable decrease in IDS, IV and FI. Prior to CCT, responders, compared to nonresponders, were characterized with higher IDS, more time in bed and higher FI, while having lower SE. Conclusions: We concluded that actigraphy assessments during regular CCT are feasible and found preliminary evidence that patients with the most disrupted sleep–wake patterns prior to treatment may benefit most from CCT.
- 7 February 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (2) , 100
Open AccessCan Physical Activity, Sleep Parameters, and Sleep–Wake Patterns Predict Outcome of Combined Chronotherapy in Mood Disorder During Routine Clinical Practice? An Exploratory Study
Background/Objectives: Combined chronotherapy (CCT), which combines repeated sleep deprivation and light therapy, is used in the clinical treatment of severe depression. Despite its potential to rapidly reduce depressive symptoms, CCT is infrequently used in clinical practice. We explored whether actigraphy-derived within-patient changes in physical activity, sleep parameters, and sleep–wake patterns prior to CCT can help identify those most likely to benefit from this treatment, supporting personalized mental health care. Methods: Actigraphy data from nine severely depressed patients were collected before, during, and after CCT. Data were assessed with a questionnaire on depressive symptoms (Inventory of Depressive Symptomatology—Self Report, IDS-SR) and actigraphy measures for sleep–wake patterns and physical activity: daily mean activity level, rhythm (intradaily variability (IV), interdaily stability (IS)), Midpoint of Sleep (MSF), time in bed, sleep efficiency (SE), and the fragmentation index (FI). Variables were compared before and after CCT by systematic visual inspection due to the small sample size. A prior set Minimal Clinically Important Difference (MCID) of a 30% change in IDS scores from before and the week after CCT was used to categorize patients as responders (n = 3) or nonresponders (n = 6) to CCT. Results: After CCT, for both responders and nonresponders, there was a notable decrease in IDS, IV and FI. Prior to CCT, responders, compared to nonresponders, were characterized with higher IDS, more time in bed and higher FI, while having lower SE. Conclusions: We concluded that actigraphy assessments during regular CCT are feasible and found preliminary evidence that patients with the most disrupted sleep–wake patterns prior to treatment may benefit most from CCT.
- Open Access
- 15 January 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (5) , 2941-2953
Psychotropic medications and their interactions with subcortical brain volume in bipolar disorder: An ENIGMA mega-analysis
MRI studies in bipolar disorder (BD) have yielded inconsistent findings, partly due to the varied use of psychotropic medications. This study utilised a mega-analysis approach, accounting for concurrent medication status (syndrome-based and Neuroscience-based Nomenclature (NbN) classifications), in order to assess the association of medication status with subcortical brain volumes in BD. Data from 2,664 BD patients and 4,065 controls (CN) were pooled from 34 research groups as part of the ENIGMA Bipolar Disorder Working Group. Standardized ENIGMA protocols were used to measure subcortical brain volumes. Linear-mixed-effects regression evaluated the association between psychotropic medications and subcortical volumes, and moderation analyses explored interactions. Medication-free patients (n = 410) showed mild ventricular enlargement (d = 0.07) and increased putamen volume (d = 0.06) compared to CN. Patients taking psychotropic medications exhibited smaller subcortical volumes (d = -0.06 to -0.11) and larger ventricles (d = 0.11 to 0.19). Use of antiepileptic and antipsychotic medications was associated with smaller hippocampal and thalamic volumes (d = -0.07 to -0.14), while NbN classification indicated that the categories of ‘valproate’ and ‘dopamine and other monoamine receptor antagonists’ are key variables when considering volume differences between BD and CN. Concurrent lithium use weakened the negative association between antiepileptic use and hippocampal volume (β = 0.19, q = 0.038) in patients. Medication status is associated with altered subcortical brain volumes in BD. The NbN classification provides a useful framework for future studies, emphasizing the need for comprehensive longitudinal research to further unravel complex clinical-pharmacological-neurobiological interactions in BD.
- 15 January 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (5) , 2941-2953
Open AccessPsychotropic medications and their interactions with subcortical brain volume in bipolar disorder: An ENIGMA mega-analysis
MRI studies in bipolar disorder (BD) have yielded inconsistent findings, partly due to the varied use of psychotropic medications. This study utilised a mega-analysis approach, accounting for concurrent medication status (syndrome-based and Neuroscience-based Nomenclature (NbN) classifications), in order to assess the association of medication status with subcortical brain volumes in BD. Data from 2,664 BD patients and 4,065 controls (CN) were pooled from 34 research groups as part of the ENIGMA Bipolar Disorder Working Group. Standardized ENIGMA protocols were used to measure subcortical brain volumes. Linear-mixed-effects regression evaluated the association between psychotropic medications and subcortical volumes, and moderation analyses explored interactions. Medication-free patients (n = 410) showed mild ventricular enlargement (d = 0.07) and increased putamen volume (d = 0.06) compared to CN. Patients taking psychotropic medications exhibited smaller subcortical volumes (d = -0.06 to -0.11) and larger ventricles (d = 0.11 to 0.19). Use of antiepileptic and antipsychotic medications was associated with smaller hippocampal and thalamic volumes (d = -0.07 to -0.14), while NbN classification indicated that the categories of ‘valproate’ and ‘dopamine and other monoamine receptor antagonists’ are key variables when considering volume differences between BD and CN. Concurrent lithium use weakened the negative association between antiepileptic use and hippocampal volume (β = 0.19, q = 0.038) in patients. Medication status is associated with altered subcortical brain volumes in BD. The NbN classification provides a useful framework for future studies, emphasizing the need for comprehensive longitudinal research to further unravel complex clinical-pharmacological-neurobiological interactions in BD.
- Open Access
Essential information about chronobiology and chronotherapy for the optimal care of people with bipolar disorders: an international expert consensus
Background Circadian dysfunction is involved in the pathophysiology of bipolar disorders (BD), and circadian-based interventions are gaining recognition in their management. Moreover, basic and epidemiologic research has generated findings inspiring circadian-informed self- and clinician-management strategies. Despite these gains, many Clinical Practice Guidelines and clinical training programs have not incorporated this evidence in their recommendations and curricula. Aims This International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force position paper reports a Delphi study-based international consensus statement on what is essential for mental health clinicians to know about the chronobiology and chronotherapy of BD. Methods An initial pool of statements was derived via review of academic and grey literatures. Statements were rated on a 5-point scale (essential; important; don’t know/depends; unimportant; should not be included). Consensus was reached when statements were rated as essential or important by ≥80% of experts. Two young persons with lived experience of BD gave feedback on acceptability. Results Thirty experts from 15 countries in Europe, North and South America, and the Asia Pacific participated (mean age 55.3 years [SD=11.8]; 40% female; 83% psychiatrists; mean clinical and research experience of 26 [SD=10.8] and 22 years [SD=12.6], respectively). Eight-hundred-and-forty-seven ratings occurred across 12 core constructs and three rounds; 470 statements were discarded after one round and 35 were discarded after rerating. Consensus was reached on 342 statements spanning four themes: basic circadian science; circadian health and disruption; chronobiology of BD; and six chronotherapies (e.g., key protocols, outcomes, side effects, risks/contraindications). Conclusions This position paper summarises an international consensus statement on the essential information about the chronobiology and chronotherapy of BD that is intended to help clinicians optimise their management of individuals with BD. This knowledge is available online ( https://osf.io/agk9y ) and its dissemination is expected to enhance the training and efficacy of clinicians globally.
Open AccessEssential information about chronobiology and chronotherapy for the optimal care of people with bipolar disorders: an international expert consensus
Background Circadian dysfunction is involved in the pathophysiology of bipolar disorders (BD), and circadian-based interventions are gaining recognition in their management. Moreover, basic and epidemiologic research has generated findings inspiring circadian-informed self- and clinician-management strategies. Despite these gains, many Clinical Practice Guidelines and clinical training programs have not incorporated this evidence in their recommendations and curricula. Aims This International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force position paper reports a Delphi study-based international consensus statement on what is essential for mental health clinicians to know about the chronobiology and chronotherapy of BD. Methods An initial pool of statements was derived via review of academic and grey literatures. Statements were rated on a 5-point scale (essential; important; don’t know/depends; unimportant; should not be included). Consensus was reached when statements were rated as essential or important by ≥80% of experts. Two young persons with lived experience of BD gave feedback on acceptability. Results Thirty experts from 15 countries in Europe, North and South America, and the Asia Pacific participated (mean age 55.3 years [SD=11.8]; 40% female; 83% psychiatrists; mean clinical and research experience of 26 [SD=10.8] and 22 years [SD=12.6], respectively). Eight-hundred-and-forty-seven ratings occurred across 12 core constructs and three rounds; 470 statements were discarded after one round and 35 were discarded after rerating. Consensus was reached on 342 statements spanning four themes: basic circadian science; circadian health and disruption; chronobiology of BD; and six chronotherapies (e.g., key protocols, outcomes, side effects, risks/contraindications). Conclusions This position paper summarises an international consensus statement on the essential information about the chronobiology and chronotherapy of BD that is intended to help clinicians optimise their management of individuals with BD. This knowledge is available online ( https://osf.io/agk9y ) and its dissemination is expected to enhance the training and efficacy of clinicians globally.